Search Results - "Croteau, S. E."

Recombinant porcine factor VIII for high‐risk surgery in paediatric congenital haemophilia A with high‐titre inhibitor by Croteau, S. E., Abajas, Y. L., Wolberg, A. S., Nielsen, B. I., Marx, G. R., Baird, C. W., Neufeld, E. J., Monahan, P. E.

“…Introduction High‐titre factor VIII (FVIII) inhibitors complicate peri‐operative haemostasis. Recombinant porcine FVIII (r‐pFVIII) may provide an alternative…”
Get full text

Fifth Åland Island conference on von Willebrand disease by Berntorp, E., Ågren, A., Aledort, L., Blombäck, M., Cnossen, M. H., Croteau, S. E., Depka, M., Federici, A. B., Goodeve, A., Goudemand, J., Mannucci, P. M., Mourik, M., Önundarson, P. T., Rodeghiero, F., Szántó, T., Windyga, J.

“…The fifth Åland Island meeting on von Willebrand disease (VWD) was held on the Åland Islands, Finland, from 22 to 24 September 2016—90 years after the first…”
Get full text

Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH by Ragni, M. V., Croteau, S. E., Morfini, M., Cnossen, M. H., Iorio, A.

“…Summary Extended half‐life proteins (EHL) are increasingly used in clinical practice, but there is no standardized approach to sampling, interpretation and…”
Get full text

Transition considerations for extended half-life factor products by Croteau, S. E., Neufeld, E. J.

Get full text

The spectrum of bleeding in women and girls with haemophilia B by Staber, J., Croteau, S. E., Davis, J., Grabowski, E. F., Kouides, P., Sidonio, R. F.

“…Although hemophilia B affects 1 in 25,000 males there may be 3 female hemophilia B carriers per affected male. This clinical review highlights the unique…”
Get full text

Author's response: 'Transition considerations for extended half-life factor products' by Croteau, S. E., Neufeld, E. J.

Get full text

Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centre-based pharmacy hit the mark? by Croteau, S. E., Saxena, K., Neufeld, E. J.

“…Summary The prescribing and dispensing of factor replacement products have come under scrutiny in recent years. Some payers are shunting patients away from…”
Get full text

Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC) by Rajpurkar, Madhvi, Croteau, Stacy E, Boggio, Lisa, Cooper, David L

“…Recombinant activated factor VII (rFVIIa; NovoSeven RT; Novo Nordisk A/S, Bagsvaerd, Denmark) is approved in the United States for the treatment of bleeding…”
Get full text